Study guide
3.1 Asthma & Chronic Obstructive Pulmonary Disease Exacerbations
CAMC Regional Medical Registration Examination Part 1 MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, Registration Framework & Test Strategy
1.1 Exam Format, Administration & Caribbean Medical Registration Pathways 1.2 Clinical Reasoning & Single-Best-Answer MCQ Test-Taking Strategy 1.3 Regional Epidemiology & Caribbean Healthcare Context
2 Chapter 2: Internal Medicine: Cardiovascular Disorders
2.1 Acute Coronary Syndromes & Myocardial Infarction Management 2.2 Heart Failure Syndromes & Cardiogenic Shock 2.3 Cardiac Arrhythmias, Conduction Blocks & BLS/ACLS Algorithms 2.4 Valvular Heart Disease, Infective Endocarditis & Hypertension
3 Chapter 3: Internal Medicine: Respiratory Medicine & Critical Care
3.1 Asthma & Chronic Obstructive Pulmonary Disease Exacerbations 3.2 Community-Acquired Pneumonia, Hospital-Acquired Pneumonia & Tuberculosis 3.3 Pulmonary Embolism, Pleural Effusion & Pneumothorax
4 Chapter 4: Internal Medicine: Endocrinology & Metabolic Disorders
4.1 Diabetes Mellitus, Diabetic Ketoacidosis & Hyperosmolar Hyperglycaemic State 4.2 Thyroid Disorders: Thyrotoxicosis, Hypothyroidism & Thyroid Storm 4.3 Adrenal Disorders, Pituitary Pathology & Calcium Homeostasis
5 Chapter 5: Internal Medicine: Gastroenterology, Hepatology & Nephrology
5.1 Upper & Lower Gastrointestinal Bleeding: Evaluation & Management 5.2 Cirrhosis, Portal Hypertension & Hepatic Encephalopathy 5.3 Acute Kidney Injury & Chronic Kidney Disease Staging 5.4 Fluid, Electrolyte & Acid-Base Emergencies
6 Chapter 6: Internal Medicine: Neurology, Haematology & Infectious Diseases
6.1 Stroke, Transient Ischaemic Attack & Acute Neurological Deficits 6.2 Sickle Cell Disease, Haemoglobinopathies & Transfusion Medicine 6.3 Dengue Fever, Arboviral Infections & Leptospirosis 6.4 HIV/AIDS, Opportunistic Infections & Antimicrobial Stewardship
7 Chapter 7: General Surgery: Acute Abdomen & Surgical Emergencies
7.1 Acute Abdomen: Peritonitis, Appendicitis & Acute Cholecystitis 7.2 Intestinal Obstruction, Bowel Ischaemia & Perforated Viscus 7.3 Abdominal Wall Hernias: Inguinal, Femoral, Umbilical & Strangulation 7.4 Upper & Lower GI Surgical Pathology & Postoperative Complications
8 Chapter 8: General Surgery: Trauma Resuscitation, Shock & Critical Care
8.1 ATLS Primary Survey & Hemorrhagic Shock Resuscitation 8.2 Thoracic Trauma: Tension Pneumothorax, Hemothorax & Flail Chest 8.3 Abdominal & Pelvic Trauma: FAST Examination & Damage Control Surgery 8.4 Traumatic Brain Injury, Burns & Wound Management
9 Chapter 9: General Surgery: Surgical Subspecialties & Perioperative Care
9.1 Urological Emergencies: Acute Retention, Renal Colic, Torsion & Hematuria 9.2 Musculoskeletal Trauma: Fractures, Dislocations & Compartment Syndrome 9.3 Preoperative Assessment, Surgical Site Infections & Fluid Management 9.4 Otolaryngology: Ear, Nose, Throat & Upper Airway Emergencies 9.5 Clinical Ophthalmology: Acute Red Eye, Glaucoma & Retinal Emergencies
10 Chapter 10: Obstetrics: Antenatal Care, Labor & Complications
10.1 Routine Antenatal Care, Screening & Fetal Assessment 10.2 Hypertensive Disorders of Pregnancy: Pre-eclampsia & Eclampsia 10.3 Antepartum Haemorrhage: Placenta Praevia & Placental Abruption 10.4 Normal Labor, Labor Dystocia & Obstetric Analgesia
11 Chapter 11: Obstetrics & Gynaecology: Postpartum & Pathology
11.1 Postpartum Haemorrhage, Normal Puerperium Physiology & Postpartum Care 11.2 Ectopic Pregnancy, Miscarriage & Gestational Trophoblastic Disease 11.3 Abnormal Uterine Bleeding & Pelvic Inflammatory Disease 11.4 Contraception, Cervical Cancer Screening & Gynaecological Malignancies 11.5 Obstetric & Gynaecological Instruments & Cervical Specimen Collection (PAP Smear Procedures)
12 Chapter 12: Paediatric Medicine: Neonatal Care, Growth & Nutrition
12.1 Neonatal Resuscitation, APGAR Scoring & Prematurity Complications 12.2 Neonatal Jaundice: Physiological, Pathological & Kernicterus 12.3 Growth Monitoring, Developmental Milestones & Failure to Thrive 12.4 Protein-Energy Malnutrition: Kwashiorkor, Marasmus & Nutritional Deficiencies
13 Chapter 13: Paediatric Medicine: Common Illnesses & Emergencies
13.1 Acute Gastroenteritis, Dehydration Assessment & WHO ORS Protocols 13.2 Paediatric Respiratory Illness: Croup, Bronchiolitis & Asthma 13.3 Childhood Infections, Exanthems & Caribbean Immunisation Schedules 13.4 Paediatric Surgical & Medical Emergencies: Intussusception & Febrile Seizures 13.5 Social Paediatrics, Child Protection & Vulnerable Child Health
14 Chapter 14: Psychiatry: Clinical Assessment & Psychopharmacology
14.1 Depressive Disorders, Bipolar Affective Disorder & Suicide Risk Assessment 14.2 Psychosis, Schizophrenia & Acute Delirium vs Dementia 14.3 Anxiety Disorders, Substance Misuse & Psychotropic Side Effects
15 Chapter 15: Community Health, Epidemiology & Preventive Medicine
15.1 Epidemiological Study Designs, Measures of Association & Bias 15.2 Screening Test Performance: Sensitivity, Specificity, PPV & NPV 15.3 Outbreak Investigation, Levels of Prevention & Caribbean NCD Control
16 Chapter 16: Internal Medicine: Rheumatology, Connective Tissue & Dermatology
16.1 Connective Tissue & Collagen Vascular Diseases 16.2 Bone & Joint Diseases: Non-Traumatic Arthropathies & Metabolic Bone Disorders 16.3 Clinical Dermatology: Common, Inflammatory, Bullous, Malignant & Drug-Induced Dermatoses
17 Chapter 17: Anaesthetics, Intensive Care & Clinical Measurements
17.1 Important Anaesthetic Techniques, Airway Management & Methods of Administration 17.2 Clinical Measurements & Intensive Care Monitoring: Cardiac Output, Arterial Blood Gases & Pulmonary Functions 17.3 Acute Pain Management, Multimodal Analgesia & Critical Care Sedation
3.1 Asthma & Chronic Obstructive Pulmonary Disease Exacerbations
Key Takeaways Explain This Topic AI
Acute severe asthma is defined by peak expiratory flow rate (PEFR) 33-50% of predicted/best, respiratory rate >= 25 breaths/min, heart rate >= 110 bpm, or inability to complete sentences in one breath.
A PaCO2 within the normal range (4.6–6.0 kPa; 35–45 mmHg) or above it in an acutely tachypneic asthmatic is an ominous sign of impending respiratory arrest due to diaphragmatic muscle exhaustion and mandates urgent ICU consultation.
First-line acute asthma pharmacotherapy comprises oxygen titrated for hypoxaemia (target SpO2 93-95%), nebulized salbutamol 5 mg, ipratropium bromide 0.5 mg, systemic corticosteroids, and intravenous magnesium sulfate 2 g over 20 minutes for severe or refractory episodes.
Controlled oxygen in COPD exacerbations targets SpO2 88-92% via 24% or 28% Venturi masks to limit oxygen-induced hypercapnia from worsening V/Q matching and reduced haemoglobin CO2 carriage through the Haldane effect.
NIV (BiPAP) is indicated for persistent COPD hypercapnic respiratory acidosis (pH <=7.35, PaCO2 >=6.0 kPa) after initial therapy. A pH below 7.25 requires urgent critical-care assessment; it does not alone exclude a monitored NIV trial with ready access to intubation.
Last updated: November 2026
Pathophysiological Divergence: Asthma vs. COPD
Acute exacerbations of obstructive airway disease represent frequent, high-stakes medical emergencies encountered across Caribbean inpatient wards and casualty departments. Although both conditions present with dyspnea, wheezing, and cough, their underlying pathophysiology dictates fundamentally different resuscitation strategies.
Asthma is characterized by chronic eosinophilic airway inflammation, mast cell activation, T-helper 2 (Th2) cytokine release (interleukins IL-4, IL-5, and IL-13), and hyperresponsiveness of bronchial smooth muscle. Airflow limitation is predominantly dynamic, episodic, and reversible following bronchodilator therapy or systemic corticosteroids.
Chronic Obstructive Pulmonary Disease (COPD) is characterized by progressive, predominantly irreversible airflow limitation caused by small airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema). Inflammation is primarily neutrophilic and CD8+ T-lymphocyte-driven, initiated by chronic noxious particle exposure—most commonly tobacco smoke, occupational dusts, or indoor biomass smoke from traditional cooking methods in rural territories.
Acute Asthma Exacerbation: Clinical Severity Stratification
Accurate classification of asthma severity determines the aggressiveness of pharmacological intervention and the disposition of the patient. Objective assessment using peak expiratory flow rate (PEFR), arterial blood gas (ABG) analysis, and vital signs is essential because subjective symptoms and chest auscultation notoriously underestimate clinical severity.
Severity Categories in Adults
Moderate Exacerbation:
- Increasing symptoms, cough, mild wheeze
- PEFR 50% to 75% of best or predicted
- Respiratory rate < 25 breaths/min; heart rate < 110 bpm
- Ability to speak in full sentences; no accessory muscle use
- Oxygen saturation (SpO2) >= 92% on room air
Severe Asthma:
- PEFR 33% to 50% of best or predicted
- Respiratory rate >= 25 breaths/min
- Heart rate >= 110 bpm
- Inability to complete sentences in one breath; marked accessory sternocleidomastoid use
- Pulsus paradoxus may be present (systolic fall > 10 mmHg during inspiration)
Life-Threatening Asthma (Any One Feature Qualifies):
- PEFR < 33% of best or predicted
- Silent chest on auscultation (minimal air entry due to extreme airway narrowing)
- Cyanosis, feeble respiratory effort, or patient exhaustion
- Bradycardia, hypotension, or cardiac dysrhythmias
- Confusion, delirium, agitation, or coma
Normal PaCO2 (4.6–6.0 kPa; 35–45 mmHg) or a higher value : In a tachypneic patient, hyperventilation should cause hypocapnia. A 'normal' PaCO2 signals respiratory muscle fatigue and impending respiratory arrest.
- Severe hypoxemia: PaO2 < 8.0 kPa (60 mmHg) or SpO2 < 92%, irrespective of oxygen treatment
- Low pH (respiratory and/or lactic acidosis)
Near-Fatal Asthma:
Raised PaCO2 and/or a requirement for mechanical ventilation with raised inflation pressures.
Stepwise Emergency Pharmacotherapy for Acute Asthma
Emergency management prioritizes reversing bronchospasm, correcting hypoxemia, and blunting airway inflammation.
Step 1: Titrated Oxygen for Hypoxaemia
If hypoxaemic, titrate supplemental oxygen to SpO2 93% to 95% in adults; use the age- or pregnancy-specific local target for children and pregnant patients. Select the device and flow needed to reach the target.
Clinical Pearl: Correct hypoxaemia promptly, but avoid uncontrolled high-concentration oxygen: excessive oxygen can raise PaCO2 in acute asthma. Titrate oxygen and reassess clinical status and blood gases when indicated.
Step 2: Inhaled Bronchodilators
Short-Acting Beta-2 Agonist (SABA): Salbutamol (albuterol) 5 mg nebulized with oxygen (or 4 to 10 puffs via metered-dose inhaler with a large-volume spacer every 15-20 minutes during the first hour). In severe or life-threatening cases, administer back-to-back or continuous nebulization (10-15 mg/hr).
Short-Acting Muscarinic Antagonist (SAMA): Ipratropium bromide 0.5 mg nebulized combined with salbutamol every 20 minutes for 3 doses, then every 4 to 6 hours. Co-administration provides synergistic bronchodilation and reduces hospital admission rates.
Step 3: Systemic Corticosteroids
Corticosteroids accelerate the resolution of airway mucosal edema and restore beta-adrenergic receptor responsiveness.
Administer oral prednisolone 40 mg to 50 mg daily (or intravenous hydrocortisone 100 mg every 6 hours if the patient is vomiting, exhausted, or unable to swallow).
Continue systemic steroids for at least 5 days or until full resolution. Tapering is unnecessary for courses lasting fewer than 14 days.
Step 4: Intravenous Magnesium Sulfate (Second-Line Resuscitation)
Indicated for severe acute asthma failing to respond promptly to nebulized bronchodilators, or any patient presenting with life-threatening features.
Administer magnesium sulfate 1.2 g to 2.0 g IV infusion over 20 minutes (diluted in 100 mL 0.9% saline).
Mechanism: Inhibits smooth muscle voltage-gated calcium channels, blocks acetylcholine release at the motor end-plate, and enhances beta-agonist bronchodilation.
Intensive Care and Mechanical Ventilation Indications
Transfer to the ICU and prepare for rapid sequence intubation (RSI) if the patient exhibits:
- Deteriorating level of consciousness, exhaustion, or respiratory arrest
- Rising PaCO2 and progressive respiratory acidosis (pH < 7.25)
- Refractory severe hypoxemia (PaO2 < 8.0 kPa) despite maximal non-invasive therapy
Caution: Non-invasive positive pressure ventilation (BiPAP/CPAP) has no established role in acute asthma and can cause barotrauma (pneumothorax, pneumomediastinum). Invasive ventilation requires low tidal volumes (6 mL/kg), slow respiratory rates, and prolonged expiratory times to minimize dynamic hyperinflation and auto-PEEP ('breath stacking').
Acute Exacerbation of COPD (AECOPD)
An acute exacerbation of COPD is defined as an acute worsening of respiratory symptoms that results in additional therapy. The primary triggers are respiratory tract infections (70-80% of cases) and environmental irritants.
Infective Etiology
Bacterial Pathogens (50%): Haemophilus influenzae , Streptococcus pneumoniae , Moraxella catarrhalis , and, in patients with severe baseline obstruction (FEV1 < 30%) or frequent hospitalizations, Pseudomonas aeruginosa .
Viral Pathogens (30-50%): Human rhinovirus, influenza, respiratory syncytial virus (RSV), and parainfluenza.
Controlled Oxygen Therapy & Hypercapnic Respiratory Failure
In severe COPD, excessive uncontrolled oxygen delivery can precipitate lethal acute-on-chronic hypercapnic respiratory failure and CO2 narcosis through several physiological mechanisms, including:
Worsening Ventilation-Perfusion (V/Q) Mismatch: High-concentration oxygen reverses hypoxic pulmonary vasoconstriction, increasing blood flow to poorly ventilated alveolar units and worsening V/Q matching and CO2 elimination.
The Haldane Effect: Deoxygenated hemoglobin binds CO2 with higher affinity than oxygenated hemoglobin. Flooding the circulation with oxygen displaces CO2 from hemoglobin into plasma, acutely elevating PaCO2.
Ventilatory Change: Oxygen may reduce ventilation in some patients, but loss of hypoxic drive is not the sole explanation for oxygen-induced hypercapnia. V/Q mismatch and altered CO2 carriage remain important; treat hypoxaemia with controlled oxygen.
Oxygen Target: Administer controlled oxygen via a 24% or 28% Venturi mask to achieve an SpO2 of 88% to 92% . Use air-driven nebulizers in hypercapnic/risk patients, with separate oxygen titrated to 88–92%. If only oxygen-driven nebulization is available, limit treatment to about 6 minutes , monitor SpO2 continuously and promptly resume controlled oxygen. Recheck blood gases within 30–60 minutes.
Pharmacological Management
Bronchodilators: Nebulized salbutamol 2.5-5 mg plus ipratropium bromide 0.5 mg every 4-6 hours.
Systemic Corticosteroids: Oral prednisolone 30 mg to 40 mg once daily for 5 days . The REDUCE trial found 5 days of prednisone 40 mg daily non-inferior to 14 days for re-exacerbation, with lower cumulative steroid exposure; measured adverse reactions did not differ significantly.
Antibiotic Indications (The Anthonisen Criteria):
Cardinal symptoms: (1) Increased dyspnea, (2) Increased sputum volume, (3) Increased sputum purulence.
Type 1 (Severe): All three cardinal symptoms present -> Antibiotics definitely indicated.
Type 2: Two cardinal symptoms present (must include increased sputum purulence) -> Antibiotics indicated.
Type 3: One cardinal symptom plus another feature (e.g. fever, wheeze, recent URTI). Hospitalization alone does not mandate antibiotics. Antibiotics are also indicated when invasive/NIV support is required or prior exacerbations had positive sputum bacterial cultures.
First-Line Antibiotics: Amoxicillin 500 mg TDS, doxycycline 100 mg BD, or azithromycin 500 mg on day 1, then 250 mg daily on days 2–5. For patients at high risk of Pseudomonas , prescribe oral ciprofloxacin 500-750 mg BD or intravenous antipseudomonal agents.
Non-Invasive Ventilation (NIV / BiPAP)
NIV is the standard of care for acute hypercapnic respiratory failure in AECOPD.
Indications: Persistent acute or acute-on-chronic respiratory acidosis ( pH <=7.35 and PaCO2 >=6.0 kPa / 45 mmHg ) despite initial optimal treatment, usually reassessed within 1 hour. pH <7.25 warrants urgent critical-care review and close monitoring, not automatic exclusion from NIV; do not delay escalation in a deteriorating patient.
Settings: Inspiratory Positive Airway Pressure (IPAP) started at 10-12 cmH2O (titrated up to 16-20 cmH2O); Expiratory Positive Airway Pressure (EPAP) 4-5 cmH2O; backup respiratory rate 12-15 breaths/min.
Contraindications: Respiratory arrest, severe hemodynamic instability, severe facial trauma/burns, bowel obstruction/vomiting (aspiration risk), inability to protect the airway or cooperate safely, or undrained pneumothorax.
Comparison: Acute Asthma vs. COPD Exacerbation Management
Clinical Parameter Acute Severe Asthma Exacerbation Acute Exacerbation of COPD (AECOPD)
Target SpO2 93% - 95% (titrated supplemental oxygen if hypoxaemic) 88% - 92% (controlled O2 via 24-28% Venturi mask)
Nebulizer Driving Gas High-flow oxygen (6 - 8 L/min) Medical air plus separately titrated O2; brief oxygen-driven fallback with continuous SpO2 monitoring
- Systemic Steroid Regimen Prednisolone 40-50 mg daily (>= 5 days) Prednisolone 30-40 mg daily (strictly 5 days)
- Second-Line Medication Intravenous Magnesium Sulfate 2 g over 20 min None routinely; optimize inhaled therapy
Role of Antibiotics Rare; only if documented bacterial infection Indicated for purulent symptom patterns, required NIV/invasive ventilation, or prior positive sputum culture
Ventilatory Support Invasive mechanical ventilation for exhaustion; avoid NIV NIV first-line for persistent hypercapnic acidosis; severe acidosis needs critical-care supervision
Key PaCO2 Pearl 'Normal' PaCO2 indicates imminent respiratory arrest Elevated PaCO2 is common; assess acute pH change